US20030158143A1 - Bispecific antisense olignucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same - Google Patents

Bispecific antisense olignucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same Download PDF

Info

Publication number
US20030158143A1
US20030158143A1 US10/346,493 US34649303A US2003158143A1 US 20030158143 A1 US20030158143 A1 US 20030158143A1 US 34649303 A US34649303 A US 34649303A US 2003158143 A1 US2003158143 A1 US 2003158143A1
Authority
US
United States
Prior art keywords
igfbp
bases
consists essentially
seq
series
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/346,493
Other languages
English (en)
Inventor
Martin Gleave
Maxim Signaevsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/346,493 priority Critical patent/US20030158143A1/en
Application filed by Individual filed Critical Individual
Assigned to UNIVERSITY OF BRITISH COLUMBIA reassignment UNIVERSITY OF BRITISH COLUMBIA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GLEAVE, MARTIN, SIGNAEVSKY, MAXIM
Publication of US20030158143A1 publication Critical patent/US20030158143A1/en
Assigned to THE UNIVERSITY OF BRITISH COLUMBIA reassignment THE UNIVERSITY OF BRITISH COLUMBIA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GLEAVE, MARTIN, SIGNAEVSKY, MAXIM
Priority to US11/287,334 priority patent/US7973017B2/en
Priority to US12/109,747 priority patent/US7928082B2/en
Priority to US12/752,581 priority patent/US9101646B2/en
Priority to US12/978,940 priority patent/US8389491B2/en
Priority to US13/087,627 priority patent/US8470796B2/en
Priority to US13/087,618 priority patent/US8252765B2/en
Priority to US13/469,402 priority patent/US8541390B2/en
Priority to US13/649,654 priority patent/US8580761B2/en
Priority to US13/904,457 priority patent/US8835401B2/en
Priority to US14/790,293 priority patent/US20160002630A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers

Definitions

  • This present application relates to bispecific antisense olignucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same in the treatment of endocrine-regulated tumors (for example, breast, prostate, ovarian and colon cancers).
  • endocrine-regulated tumors for example, breast, prostate, ovarian and colon cancers.
  • Prostate cancer is the most common cancer that affects men, and the second leading cause of cancer deaths in men in the Western world. Because prostate cancer is an androgen-sensitive tumor, androgen withdrawal, for example via castration, is utilized in some therapeutic regimens for patients with advanced prostate cancer. Androgen withdrawal leads to extensive apoptosis in the prostate tumor, and hence to a regression of the disease. However, castration-induced apoptosis is not complete, and a progression of surviving tumor cells to androgen-independence ultimately occurs. This progression is the main obstacle to improving survival and quality of life, and efforts have therefore been made to target androgen-independent cells.
  • IGF-I and IGF-II are potent mitogens for many normal and malignant cells. Accumulating evidence suggests that IGFs play an important role in the pathophysiology of prostatic disease and breast cancer. Boudon et al., J. Clin. Endocrin. Metab. 81: 612-617 (1996); Angelloz-Nicoud et al., Endocrinology 136: 5485-5492 (1995); Nickerson et al., Endocrinology 139: 807-810 (1998); Figueroa et al., J. Urol. 159: 1379-1383 (1998).
  • IGFBPs The biological response to IGF's is regulated by various factors, including IGFBPs.
  • IGFBPs six IGFBPs have been identified whose function is believed to involve modulation of the biological actions of the IGFs through high affinity interactions. Rajaram et al., Endocrin. Rev. 18: 801-813 (1997).
  • some evidence suggests biological activity for IGFBPs that are independent of IGFs, Id., Andress et al., J. Biol. Chem. 267: 22467-22472 (1992); Oh et al., J. Biol. Chem. 268: 14964-14971 (1993), and both stimulatory and inhibitory effects of IGFBPs on cell proliferation have been reported under various experimental conditions.
  • PCT Publication WO 01/05435 which is incorporated herein by reference, describes a method for treating hormone-regulated tumors (for example, breast and prostatic tumors) in mammals, including humans, by administration of an antisense oligodeoxynucleotide which is complementary to a portion of the gene encoding IGFBP-5.
  • PCT Publication No. WO 02/22642 which is incorporated herein by reference, describes a method are provided for the treatment of prostate and other endocrine tumors in mammals, including humans, by administration of an antisense oligodeoxynucleotide which is complementary to a portion of the gene encoding IGFBP-2.
  • the present invention utilizes bispecific antisense oligodeoxynucleotides targeted to both IBFBP-2 and IGFBP-5 as a treatment for endocrine-regulated cancers.
  • Antisense oligodeoxynucleotides are chemically modified stretches of single-stranded DNA that are complementary to mRNA regions of a target gene, and thereby effectively inhibit gene expression by forming RNA/DNA duplexes. Figueroa, et al., J. Urol., 159:1379-1383 (1998).
  • Phosphorothioate oligodeoxynucleotides are stabilized to resist nuclease digestion by substituting one of the nonbridging phosphoryl oxygen of DNA with a sulfur.
  • the present invention provides a method for treating endocrine-regulated tumors (for example, breast, prostate, ovarian and colon cancers) in mammals, including humans, by administration of a bispecific antisense oligodeoxynucleotide which is complementary to portions of both the gene encoding IGFBP-2 and the gene encoding IGFBP-5.
  • a bispecific antisense oligodeoxynucleotide which is complementary to portions of both the gene encoding IGFBP-2 and the gene encoding IGFBP-5.
  • the administration of such an oligodeoxynucleotide was shown to reduce levels of both IGFBP-2 and IGFBP-5 in PC3 and LNCaP cells, and the reduction of expression of the proteins has been previously shown to reduce proliferation of tumor cells, and also to delay the progression to androgen independence.
  • a bispecific antisense oligodeoxynucleotide which is complementary to portions of both the nucleic acid sequence encoding IGFBP-2 and the nucleic acid sequence encoding IGFBP-5, and which hybridizes with such sequences to inhibit or otherwise reduce the expression of IGFBP-2 and IGFBP-5.
  • the application further provides bi-specific antisense sequences that can be used in the method of the invention.
  • FIG. 1 the amount of IGBFP-2 and IGBFP-5 expression observed in LNCaP and PC3 cells, respectively, upon administration of the three bispecific antisense oligonucleotide, a mismatch control (MM), or no olignucleotide (control).
  • MM mismatch control
  • control no olignucleotide
  • FIG. 2 shows the increase in IGFBP-2 expression in prostate cancer cells during progression to androgen indpendence.
  • FIGS. 3 A-E shows inhibition of IGFBP-2 and 5 in prostate cancer and bone cells using various antisense oligonucleotides.
  • FIGS. 4 and 5 show real time PCR results for levels of IGFBP-2 and IGFBP-5 in RT4 bladder cancer cells after treatment with antisense oligonucleotides of the invention.
  • FIG. 6 shows results of real time PCR measurement of IGFBP-5 in MSF human fetal fibroblast cells after antisense treatment.
  • FIG. 7 shows the results of real time PCR measurements of IGFBP-2 and IGFBP-5 LNCaP/msf in mixed tumors and in intact fetal bone fragments
  • the present invention provides bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding IGFBP-2 and the gene encoding IGFBP-5, and that is sufficient length to act as an inhibitor of the effective amount of IGFBP-2 and IGFBP-5 (in general at least 15 bases).
  • this language means that substantially all of the antisense oligonucleotide is complementary to a portion of each gene sequence.
  • the invention does not, however, exclude minor modifications in sequence, such as the addition of one or two terminal bases, or single base substitutions which might depart from perfect complementarity but which still function as an inhibitor of the effective amount of IGFBP-2 and IGFBP-5.
  • the phrase “inhibitor of the effective amount” takes into account the fact that antisense oligonucleotides may function by different mechanisms.
  • the effective amount of IGFBP-2 or IGFBP-5 is the amount that is present in a functional state in the cell. Reduction of this amount by administration of antisense oligonucleotides may occur through restricting production of the IGFBP (at the transcription or translation level) or by degrading the IGFBP at a rate faster than it is being produced. Further, it will be appreciated that the inhibition which is referred to is one which occurs when the IGFBP would otherwise be present if the antisense oligonucleotide had not been administered. As discussed below, not all cells that are potential therapeutic targets express both IGFBP-2 and IGFBP-5.
  • Specific antisense oligonucleotides according to the invention consist essentially of a series of bases as set forth in Seq. ID. No. 1 through 7. These sequences are set forth in Table 1. TABLE 1 Seq. ID NO. Sequence 1 ggtgtagacgccgcacg 2 gcagcgcagccctgg 3 gcagcagccgcageccggctcc 4 agccgcagcccggctcct 5 cagcagccgcagcccggctc 6 gcagcagcegcagcccggct 7 agcagccgcagcecggctccc
  • the antisense oligonucleotides employed may be modified to increase the stability of the antisense oligonucleotide in vivo.
  • the antisense oligonucleotides may be employed as phosphorothioate derivatives (replacement of a non-bridging phosphoryl oxygen atom with a sulfur atom) which have increased resistance to nuclease digestion.
  • Increased antisense oligonucleotide stability can also be achieved using molecules with 2-methoxyethyl (MOE) substituted backbones as described generally in U.S. Pat. No. 6,451,991 and U.S. patent application Ser. No. 10/080,794 which are incorporated herein by reference.
  • MOE 2-methoxyethyl
  • compositions of the present invention can be used for treatment of endocrine-regulated tumors (for example, breast, prostate, ovarian and colon cancers) in mammals, including humans, by administration of a bispecific antisense oligonucleotide in accordance with the invention.
  • Administration of antisense oligonucleotides can be carried out using the various mechanisms known in the art, including naked administration and administration in pharmaceutically acceptable carriers.
  • lipid carriers for antisense delivery are described in U.S. Pat. Nos. 5,855,911 and 5,417,978 which are incorporated herein by reference.
  • the antisense is administered by intravenous, intraperitoneal, subcutaneous or oral routes.
  • the carrier is generally free from substances which produce toxic or other harmful reactions when administered to humans.
  • the amount of antisense oligonucleotide administered is one effective to reduce the effective amount of levels of IGFBP-2 and/or IGFBP-5 in the endocrine-regulated tumor cell of concern.
  • applicants do not intend to be bound by any specific mechanism by which this reduction may occur, although it is noted that the reduction may occur as a result of reduced expression of IGFBP-2 and -5 if the antisense molecule interferes with translation of the mRNA, or via an RNase mediated mechanism.
  • the appropriate therapeutic amount will vary both with the effectiveness of the specific antisense oligonucleotide employed, and with the nature of any carrier used. The determination of appropriate amounts for any given composition is within the skill in the art, through standard series of tests designed to assess appropriate therapeutic levels.
  • the method for treating endocrine-regulated cancer in accordance with the invention may further include administration of chemotherapy agents and/or additional antisense oligonucleotides directed at different targets.
  • chemotherapy agents such as taxol (paclitaxel or docetaxel) and mitoxanthrone may be used.
  • combinations of the bispecific antisense oligonucleotide of the invention with other antisense sequences such as antisense Bcl-2 oligonucleotide, TRPM-2 (clusterin) oligonucleotide, IGFBP-2 or IGFBP-5 oligonucleotide may be used.
  • the effectiveness of the present invention is founded on solid theoretical and experimental bases. Activation of alternative growth factor pathways following androgen withdrawal is one mechanism mediating androgen independent (AI) progression in advanced prostate cancer.
  • Insulin-like growth factor-I (IGF-I) activation is modulated by a family of insulin-like growth factor binding proteins (IGFBPs).
  • IGFBP-2 and IGFBP-5 are among the most commonly over-expressed genes in hormone refractory prostate cancer, the functional significance of changes in IGF-I signaling during AI progression remain poorly defined.
  • AI progression of prostate cancer leads to treatment resistance and ultimately culminates in the development of bone metastases, the most ominous sign of clinical progression in prostate cancer patients with advanced disease. This development usually precedes death by 12-18 months.
  • IGFBP-5 The bone environment, particularly rich in IGFBP-5, has long been identified as an attractive “soil” for supporting prostate cancer metastasis.
  • the crucial IGF-1 signaling components IGFBP-2 and IGFBP-5 may not only be key to AI progression but also to the site-specific metastasis of prostate cancer.
  • IGFBP-2 mRNA and protein levels increase 2-3-fold after androgen withdrawal in LNCaP cells in vitro in LNCaP tumors during AI progression in vivo. Increased IGFBP-2 levels after castration were also identified using a human prostate tissue microarray of untreated and post-hormone therapy-treated prostatectomy specimen. LNCaP cell transfectants (LNBP-2) that stably over-expressed IGFBP-2 had a shorter cell doubling-time and a lower rate of apoptosis in the absence of androgens. Reporter assays demonstrated that this increased growth potential did not result from IGFBP-2-mediated transcription of androgen-response elements.
  • the LNBP-2 cell line formed significantly more tumors in castrate mice and progressed to androgen independence more rapidly compared with a control cell line.
  • Antisense oligonucleotides targeting IGFBP-2 reduced IGFBP-2 mRNA and protein expression by >70% in a dose-dependent and sequence-specific manner.
  • Antisense oligonucleotide-induced decreases in IGFBP-2 reduced LNCaP cell growth rates and increased apoptosis 3-fold.
  • LNCaP tumor growth and serum PSA levels in mice treated with castration plus adjuvant IGFBP-2 antisense oligonucleotide s were significantly reduced compared to mismatch control oligonucleotides.
  • IGFBP-5 gain-of-function and loss-of-function analyses of IGFBP-5 in IGFBP-5 expressing prostate cancer models.
  • the growth rates of IGFBP-5 transfected LNCaP cells were significantly faster compared to either the parental or vector-only transfected LNCaP cells in both the presence and absence of dihydrotestosterone.
  • IGFBP-5-induced increases in LNCaP cell proliferation occurs through both IGF-I-dependent and -independent pathways, with corresponding increases in the cyclin D1 mRNA expression and the fraction of cells in S+G2/M phases of the cell cycle.
  • Akt/protein kinase B PKT
  • PI3K phosphatidylinositol 3′-kinase
  • IGFBP-5 overexpression in prostate cancer cells after castration is an adaptive cell survival mechanism that helps potentiate the antiapoptotic and mitogenic effects of IGF-I, thereby accelerating progression to androgen-independence through activation of the PI3K-Akt/PKB signaling pathway.
  • Systemic administration of IGFBP-5 antisense oligonucleotides significantly delayed time to progression to androgen independence and inhibited growth of AI recurrent tumors. IGFBP-5 expression in human bone was confirmed.
  • Inhibiting IGFBP-2 and IGFBP-5 expression using targeted antisense technologies provides a treatment platform to delay AI progression and bone metastasis in prostate cancer patients and patients with other malignancies expressing these key regulators of IGF-1 signaling.
  • By targeting both IGFBP-2 and IGFBP-5 simultaneously with a single antisense oligonucleotide the complications associated with use of a cocktail of antisense oligonucleotides targeting either of these compounds separately are avoided.
  • LNCaP cells were treated with treated with 500 nM concentrations of antisense oligonucleotides of Seq. ID Nos. 1, 2 or 3 or a mismatch control. Levels of IGFBP-2 were measured. The result are summarized in FIG. 1A.
  • PC3 cells were treated with treated with 500 nM concentrations of antisense oligonucleotides of Seq. ID Nos. 1, 2 or 3 or a mismatch control. Levels of IGFBP-5 were measured. The result are summarized in FIG. 1B.
  • Bispecific antisense oligonucleotides were used to treat PC3, LNCaP and bone cells at concentration of 500 nm, and the amount of inhibition of IGFBP-2 or IGFBP-5 was measured using real time PCR. Oligonucleotides of Seq. ID Nos. 2, 4, 5 and 7 were tested, and all were effective to reduce the detected amount of the IGFBP measured.
  • FIG. 3A Reductions of up to 70% in IGFBP-2 levels were also observed in A549 lung cells using 500 nM of Seq. ID Nos. 4 and 5.
  • Seq. ID No. 4 500 nM was also shown to be effective to inhibit cell growth of LNCaP cells and reduce the cell number by more than 90%.
  • FIGS. 3D and E respectively show results for inhibition of IGFBP-5 levels in PC3 cells with 500 nM of Seq ID Nos. 1, 2, 4 5, 6 and 7; and inhibition of IGBFP-5 levels in human fetal bone fobroblast cells with 500 nM of Seq. ID Nos. 1, 2, 4, 5, 6 and 7.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US10/346,493 2002-01-17 2003-01-17 Bispecific antisense olignucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same Abandoned US20030158143A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US10/346,493 US20030158143A1 (en) 2002-01-17 2003-01-17 Bispecific antisense olignucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
US11/287,334 US7973017B2 (en) 2002-01-17 2005-11-23 Treatment of cancer by inhibition of IGFBP's and clusterin
US12/109,747 US7928082B2 (en) 2002-01-17 2008-04-25 Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
US12/752,581 US9101646B2 (en) 2002-01-17 2010-04-01 Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
US12/978,940 US8389491B2 (en) 2002-01-17 2010-12-27 Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
US13/087,618 US8252765B2 (en) 2002-01-17 2011-04-15 Treatment of cancer by inhibition of IGFBPs and clusterin
US13/087,627 US8470796B2 (en) 2002-01-17 2011-04-15 Treatment of cancer by inhibition of IGFBPs and clusterin
US13/469,402 US8541390B2 (en) 2002-01-17 2012-05-11 Treatment of cancer by inhibition of IGFBPs and clusterin
US13/649,654 US8580761B2 (en) 2002-01-17 2012-10-11 Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
US13/904,457 US8835401B2 (en) 2002-01-17 2013-05-29 Treatment of cancer by inhibition of IGFBPs and clusterin
US14/790,293 US20160002630A1 (en) 2002-01-17 2015-07-02 Bispecific Antisense Oligonucleotides that Inhibit IGFBP-2 and IGFBP-5 and Methods of Using Same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35004602P 2002-01-17 2002-01-17
US10/346,493 US20030158143A1 (en) 2002-01-17 2003-01-17 Bispecific antisense olignucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US11/287,334 Continuation-In-Part US7973017B2 (en) 2002-01-17 2005-11-23 Treatment of cancer by inhibition of IGFBP's and clusterin
US11/287,334 Continuation US7973017B2 (en) 2002-01-17 2005-11-23 Treatment of cancer by inhibition of IGFBP's and clusterin
US12/109,747 Division US7928082B2 (en) 2002-01-17 2008-04-25 Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same

Publications (1)

Publication Number Publication Date
US20030158143A1 true US20030158143A1 (en) 2003-08-21

Family

ID=27613360

Family Applications (11)

Application Number Title Priority Date Filing Date
US10/346,493 Abandoned US20030158143A1 (en) 2002-01-17 2003-01-17 Bispecific antisense olignucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
US11/287,334 Expired - Fee Related US7973017B2 (en) 2002-01-17 2005-11-23 Treatment of cancer by inhibition of IGFBP's and clusterin
US12/109,747 Expired - Fee Related US7928082B2 (en) 2002-01-17 2008-04-25 Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
US12/752,581 Expired - Fee Related US9101646B2 (en) 2002-01-17 2010-04-01 Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
US12/978,940 Expired - Fee Related US8389491B2 (en) 2002-01-17 2010-12-27 Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
US13/087,618 Expired - Fee Related US8252765B2 (en) 2002-01-17 2011-04-15 Treatment of cancer by inhibition of IGFBPs and clusterin
US13/087,627 Expired - Fee Related US8470796B2 (en) 2002-01-17 2011-04-15 Treatment of cancer by inhibition of IGFBPs and clusterin
US13/469,402 Expired - Fee Related US8541390B2 (en) 2002-01-17 2012-05-11 Treatment of cancer by inhibition of IGFBPs and clusterin
US13/649,654 Expired - Fee Related US8580761B2 (en) 2002-01-17 2012-10-11 Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
US13/904,457 Expired - Fee Related US8835401B2 (en) 2002-01-17 2013-05-29 Treatment of cancer by inhibition of IGFBPs and clusterin
US14/790,293 Abandoned US20160002630A1 (en) 2002-01-17 2015-07-02 Bispecific Antisense Oligonucleotides that Inhibit IGFBP-2 and IGFBP-5 and Methods of Using Same

Family Applications After (10)

Application Number Title Priority Date Filing Date
US11/287,334 Expired - Fee Related US7973017B2 (en) 2002-01-17 2005-11-23 Treatment of cancer by inhibition of IGFBP's and clusterin
US12/109,747 Expired - Fee Related US7928082B2 (en) 2002-01-17 2008-04-25 Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
US12/752,581 Expired - Fee Related US9101646B2 (en) 2002-01-17 2010-04-01 Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
US12/978,940 Expired - Fee Related US8389491B2 (en) 2002-01-17 2010-12-27 Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
US13/087,618 Expired - Fee Related US8252765B2 (en) 2002-01-17 2011-04-15 Treatment of cancer by inhibition of IGFBPs and clusterin
US13/087,627 Expired - Fee Related US8470796B2 (en) 2002-01-17 2011-04-15 Treatment of cancer by inhibition of IGFBPs and clusterin
US13/469,402 Expired - Fee Related US8541390B2 (en) 2002-01-17 2012-05-11 Treatment of cancer by inhibition of IGFBPs and clusterin
US13/649,654 Expired - Fee Related US8580761B2 (en) 2002-01-17 2012-10-11 Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
US13/904,457 Expired - Fee Related US8835401B2 (en) 2002-01-17 2013-05-29 Treatment of cancer by inhibition of IGFBPs and clusterin
US14/790,293 Abandoned US20160002630A1 (en) 2002-01-17 2015-07-02 Bispecific Antisense Oligonucleotides that Inhibit IGFBP-2 and IGFBP-5 and Methods of Using Same

Country Status (15)

Country Link
US (11) US20030158143A1 (ja)
EP (1) EP1465995B1 (ja)
JP (1) JP4491240B2 (ja)
KR (2) KR101166214B1 (ja)
AT (1) ATE402999T1 (ja)
AU (1) AU2003237616B2 (ja)
CA (1) CA2469685C (ja)
DE (1) DE60322509D1 (ja)
DK (1) DK1465995T3 (ja)
ES (1) ES2307942T3 (ja)
HU (1) HU229452B1 (ja)
IL (2) IL162540A0 (ja)
NO (1) NO333017B1 (ja)
NZ (1) NZ533126A (ja)
WO (1) WO2003062421A1 (ja)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060009405A1 (en) * 2003-10-01 2006-01-12 The University Of British Columbia Bispecific Oligonucleotide for the Treatment of CNS Malignancies
US20060122141A1 (en) * 2002-01-17 2006-06-08 The University Of British Columbia Treatment of cancer by inhibition of IGFBP's and clusterin
US20060166916A1 (en) * 2004-07-01 2006-07-27 Mathison Brian H Composite polynucleic acid therapeutics
US20080014198A1 (en) * 2004-11-23 2008-01-17 The University Of British Columbia Treatment of Cancer With a Combination of an Agent that Perturbs the EGF Signaling Pathway and an Oligonucleotide that Reduces Clusterin Levels
US20080119425A1 (en) * 2004-04-02 2008-05-22 The University Of British Columbia Clusterin Antisense Therapy for Treatment of Cancer
WO2013039859A1 (en) 2011-09-12 2013-03-21 Gray Lloyd S Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
US20150157656A1 (en) * 2013-12-06 2015-06-11 The University Of British Columbia Method for Treatment of Castration-Resistant Prostate Cancer
US9074209B2 (en) 1999-02-26 2015-07-07 The University Of British Columbia TRPM-2 antisense therapy
US9095602B2 (en) 2000-09-28 2015-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
US9427429B2 (en) 2010-03-01 2016-08-30 Tau Therapeutics Llc Cancer diagnosis and imaging
WO2017070680A1 (en) 2015-10-22 2017-04-27 Cavion Llc Methods for treating angelman syndrome and related disorders
US11130750B2 (en) 2017-02-15 2021-09-28 Cavion, Inc. Calcium channel inhibitors
US11311522B1 (en) 2018-10-03 2022-04-26 Cavion, Inc. Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
US11324733B2 (en) 2017-04-26 2022-05-10 Cavion, Inc. Methods for improving memory and cognition and for treating memory and cognitive disorders

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
KR101212512B1 (ko) 2002-08-21 2012-12-26 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
US7285541B2 (en) * 2002-08-21 2007-10-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
US20040142359A1 (en) * 2002-11-14 2004-07-22 Wyeth Methods and compositions for treating neurological disorders
US7315916B2 (en) * 2004-12-16 2008-01-01 Sandisk Corporation Scratch pad block
AU2006291990B2 (en) 2005-09-13 2012-05-31 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
CA2703795A1 (en) * 2006-10-27 2008-05-02 Mount Sinai Hospital Endometrial phase or endometrial cancer biomarkers
CN102666585B (zh) 2009-11-24 2015-02-18 阿莱斯亚生物疗法股份有限公司 抗簇蛋白抗体和抗原结合片段及其减小肿瘤体积的用途
JP2014520081A (ja) * 2011-05-19 2014-08-21 テバ ファーマシューティカル インダストリーズ リミティド 非小細胞肺癌を処置するための方法
WO2013123588A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
KR20180091816A (ko) 2015-10-14 2018-08-16 바이오-패쓰 홀딩스 인크. 리포좀 제제를 위한 p-에톡시 핵산
US10496215B2 (en) * 2016-04-29 2019-12-03 Synaptics Incorporated Sensing for touch and force
MX2019003070A (es) 2016-09-16 2019-10-14 Bio Path Holdings Inc Terapia de combinacion con oligonucleotidos antisentido liposomales.
CA3058018A1 (en) 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for stat3 inhibition
KR102068302B1 (ko) 2018-07-25 2020-01-20 정준모 봉투 고정장치

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5929040A (en) * 1994-07-08 1999-07-27 Royal Children's Hospital Research Foundation Method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
US20030087857A1 (en) * 2001-10-09 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0546074B1 (en) 1990-08-28 2001-11-14 Chiron Corporation Genetic material encoding igfbp-5
EP0546110B1 (en) 1990-08-28 2001-11-14 Chiron Corporation New insulin-like growth factor binding protein igfbp-5
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
AU1313095A (en) * 1993-12-23 1995-07-10 Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbb plays a role
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
BR9707529A (pt) * 1996-02-14 2000-01-04 Isis Pharmaceuticals Inc Oligunucleotìdeo especificamente hibridizável com dna ou rna.
US5910583A (en) * 1996-11-04 1999-06-08 Duke University Antisense oligonucleotides against ERBB-2
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6210892B1 (en) * 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
WO2000031048A1 (en) 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
AU3116800A (en) 1998-12-11 2000-06-26 Research Foundation Of The State University Of New York, The Compositions and methods for altering cell migration
HU227190B1 (en) * 1999-02-26 2010-10-28 Univ British Columbia Trpm-2 antisense therapy
US6900187B2 (en) 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
WO2000069454A1 (en) * 1999-05-17 2000-11-23 Board Of Regents, The University Of Texas System Suppression of endogenous igfbp-2 to inhibit cancer
CA2376284A1 (en) * 1999-06-21 2000-12-28 Murdoch Childrens Research Institute A method for the prophylaxis and/or treatment of medical disorders
WO2001001748A2 (en) 1999-07-02 2001-01-11 Genentech, Inc. Peptide compounds that bind her2
EP1200579B1 (en) * 1999-07-19 2008-04-23 The University of British Columbia Antisense therapy for hormone-regulated tumors
US6310047B1 (en) * 1999-08-24 2001-10-30 Virginia Commonwealth University High affinity DNA binding compounds as adjuvants in antisense technology
WO2001046455A2 (en) 1999-12-21 2001-06-28 Yale University Survivin promotion of angiogenesis
US7569551B2 (en) * 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
AU2001249622B2 (en) * 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
DE60144525D1 (de) * 2000-09-14 2011-06-09 Univ British Columbia Des protein (igfbp)-2-oligodeoxynukleotide zur behandlung von prostatakrebs
HU230458B1 (hu) * 2000-12-01 2016-07-28 Europäisches Laboratorium für Molekularbiologie (EMBL) Az RNS interferenciát közvetítő kis RNS molekulák
WO2002097114A2 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
DE10152005A1 (de) 2001-10-22 2003-04-30 Bayer Cropscience Ag Pyrazolylsubstituierte Heterocyclen
US20050123896A1 (en) 2001-10-25 2005-06-09 Benz Christopher C. Screening system for modulators of her2 mediated transcription and her2 modulators identified thereby
NZ533126A (en) * 2002-01-17 2006-04-28 Univ British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
US7019017B2 (en) * 2002-05-14 2006-03-28 Baylor College Of Medicine Small molecule inhibitors of HER2 expression
KR101212512B1 (ko) 2002-08-21 2012-12-26 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
US7285541B2 (en) 2002-08-21 2007-10-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
WO2004092378A2 (en) * 2003-04-18 2004-10-28 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
WO2005030260A1 (en) * 2003-10-01 2005-04-07 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
PE20121495A1 (es) * 2009-07-30 2012-11-19 Antisense Pharma Gmbh Combinacion de un agente quimioterapeutico y un inhibidor del sistema tgf-beta

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5929040A (en) * 1994-07-08 1999-07-27 Royal Children's Hospital Research Foundation Method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US6284741B1 (en) * 1994-07-08 2001-09-04 Royal Children's Hospital Research Foundation Method for the prophylaxis and/or treatment of proliferative and /or inflammatory skin disorders
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
US20030087857A1 (en) * 2001-10-09 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9074209B2 (en) 1999-02-26 2015-07-07 The University Of British Columbia TRPM-2 antisense therapy
US9095602B2 (en) 2000-09-28 2015-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
US20110190382A1 (en) * 2002-01-17 2011-08-04 The University Of British Columbia Treatment of Cancer by Inhibition of IGFBPs and Clusterin
US20060122141A1 (en) * 2002-01-17 2006-06-08 The University Of British Columbia Treatment of cancer by inhibition of IGFBP's and clusterin
US8835401B2 (en) 2002-01-17 2014-09-16 The University Of British Columbia Treatment of cancer by inhibition of IGFBPs and clusterin
US8541390B2 (en) 2002-01-17 2013-09-24 The University Of British Columbia Treatment of cancer by inhibition of IGFBPs and clusterin
US8470796B2 (en) 2002-01-17 2013-06-25 The University Of British Columbia Treatment of cancer by inhibition of IGFBPs and clusterin
US8252765B2 (en) 2002-01-17 2012-08-28 The University Of British Columbia Treatment of cancer by inhibition of IGFBPs and clusterin
US20110196019A1 (en) * 2002-01-17 2011-08-11 The University Of British Columbia Treatment of Cancer by Inhibition of IGFBPs and Clusterin
US7973017B2 (en) 2002-01-17 2011-07-05 The University Of British Columbia Treatment of cancer by inhibition of IGFBP's and clusterin
US8168610B2 (en) 2003-10-01 2012-05-01 The University Of British Columbia Bispecific oligonucleotide for the treatment of CNS malignancies
US20110152354A1 (en) * 2003-10-01 2011-06-23 The University Of British Columbia Bispecific Oligonucleotide for the Treatment of CNS Malignancies
US20060009405A1 (en) * 2003-10-01 2006-01-12 The University Of British Columbia Bispecific Oligonucleotide for the Treatment of CNS Malignancies
US7932234B2 (en) * 2003-10-01 2011-04-26 The University Of British Columbia Bispecific oligonucleotide for the treatment of CNS malignancies
US20080119425A1 (en) * 2004-04-02 2008-05-22 The University Of British Columbia Clusterin Antisense Therapy for Treatment of Cancer
US9200285B2 (en) 2004-04-02 2015-12-01 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
US7482158B2 (en) 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
US20060166916A1 (en) * 2004-07-01 2006-07-27 Mathison Brian H Composite polynucleic acid therapeutics
US20110142827A1 (en) * 2004-11-23 2011-06-16 The University Of British Columbia Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels
US20080014198A1 (en) * 2004-11-23 2008-01-17 The University Of British Columbia Treatment of Cancer With a Combination of an Agent that Perturbs the EGF Signaling Pathway and an Oligonucleotide that Reduces Clusterin Levels
US9427429B2 (en) 2010-03-01 2016-08-30 Tau Therapeutics Llc Cancer diagnosis and imaging
WO2013039859A1 (en) 2011-09-12 2013-03-21 Gray Lloyd S Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
US20150157656A1 (en) * 2013-12-06 2015-06-11 The University Of British Columbia Method for Treatment of Castration-Resistant Prostate Cancer
US9205102B2 (en) * 2013-12-06 2015-12-08 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
WO2017070680A1 (en) 2015-10-22 2017-04-27 Cavion Llc Methods for treating angelman syndrome and related disorders
US11273218B2 (en) 2015-10-22 2022-03-15 Cavion, Inc. Methods for treating Angelman syndrome and related disorders
US11130750B2 (en) 2017-02-15 2021-09-28 Cavion, Inc. Calcium channel inhibitors
US11324733B2 (en) 2017-04-26 2022-05-10 Cavion, Inc. Methods for improving memory and cognition and for treating memory and cognitive disorders
US11311522B1 (en) 2018-10-03 2022-04-26 Cavion, Inc. Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide

Also Published As

Publication number Publication date
IL162540A0 (en) 2005-11-20
DE60322509D1 (de) 2008-09-11
CA2469685C (en) 2013-03-12
US20110190382A1 (en) 2011-08-04
DK1465995T3 (da) 2008-10-20
JP4491240B2 (ja) 2010-06-30
WO2003062421A1 (en) 2003-07-31
US20100267808A1 (en) 2010-10-21
US20130096180A1 (en) 2013-04-18
US8470796B2 (en) 2013-06-25
IL162540A (en) 2011-06-30
KR101265180B1 (ko) 2013-05-29
EP1465995A1 (en) 2004-10-13
JP2005514948A (ja) 2005-05-26
NO333017B1 (no) 2013-02-18
KR101166214B1 (ko) 2012-07-16
KR20110026023A (ko) 2011-03-14
US8389491B2 (en) 2013-03-05
ES2307942T3 (es) 2008-12-01
HUP0402543A2 (hu) 2005-03-29
US8835401B2 (en) 2014-09-16
US20080261912A1 (en) 2008-10-23
AU2003237616B2 (en) 2007-07-05
US20160002630A1 (en) 2016-01-07
KR20040085150A (ko) 2004-10-07
US8541390B2 (en) 2013-09-24
US8252765B2 (en) 2012-08-28
US8580761B2 (en) 2013-11-12
US7928082B2 (en) 2011-04-19
US9101646B2 (en) 2015-08-11
US20110196019A1 (en) 2011-08-11
US20060122141A1 (en) 2006-06-08
NZ533126A (en) 2006-04-28
ATE402999T1 (de) 2008-08-15
US20120220646A1 (en) 2012-08-30
US20120077861A1 (en) 2012-03-29
HU229452B1 (en) 2013-12-30
US7973017B2 (en) 2011-07-05
EP1465995B1 (en) 2008-07-30
US20130303592A1 (en) 2013-11-14
HUP0402543A3 (en) 2012-09-28
NO20043401L (no) 2004-10-13
CA2469685A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
US8580761B2 (en) Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
AU2003237616A1 (en) Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
EP1200579B1 (en) Antisense therapy for hormone-regulated tumors
US7196067B2 (en) Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
AU2001290920A1 (en) Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
US7491816B2 (en) Antisense therapy for hormone-regulated tumors

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERSITY OF BRITISH COLUMBIA, BRITISH COLUMBIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GLEAVE, MARTIN;SIGNAEVSKY, MAXIM;REEL/FRAME:013981/0961

Effective date: 20030220

AS Assignment

Owner name: THE UNIVERSITY OF BRITISH COLUMBIA, BRITISH COLUMB

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GLEAVE, MARTIN;SIGNAEVSKY, MAXIM;REEL/FRAME:014557/0194

Effective date: 20030220

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION